Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1 2 in black African healthy Beninese subjects

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 2, 2012, Pages 125-132

  Allabi, Aurel Constant ^a   Horsmans, Yves ^b   Alvarez, Jean Claude ^c   Bigot, André ^d   Verbeeck, Roger K ^b,e   Yasar, Umit ^f   Gala, Jean Luc ^b  

^a Faculte des Sciences de la Sante de Cotonou   (Benin)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d UAC   (Benin)

^e RHODES UNIVERSITY   (South Africa)

^f HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acenocoumarol; African; Benin; CYP2C9; INR; VKORC1

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE;

ADULT; AGE DISTRIBUTION; ARTICLE; BENIN; BODY MASS; BODY WEIGHT; CYP2C9 GENE; DRUG BLOOD LEVEL; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; MALE; NEGRO; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VKORC1 GENE;

ACENOCOUMAROL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BENIN; BODY MASS INDEX; CHROMATOGRAPHY, LIQUID; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; TANDEM MASS SPECTROMETRY;

EID: 84863716564     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0056-7     Document Type: Article

References (39)

1. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y (2003) Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56:653-657
2. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U (2004) Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 76:113-118
3. Allabi AC, Gala JL, Horsmans Y (2005) CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 15:779-786
4. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79:291-302
5. Belle DJ, Singh H (2008) Genetic factors in drug metabolism. Am Fam Physician 77:1553-1560
6. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527-537
7. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140
8. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87:459-464
9. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-Anticoagulant effect of warfarin. Blood 105:645-649
10. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C95) expressed among African Americans. Mol Pharmacol 60:382-387
11. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326-331
12. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94:773-779
13. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539-547
14. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204-212
15. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43:740-744
16. Markatos CN, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I, Spiliotopoulou I, Travlou A (2008) VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 9:1631-1638
17. Meinertz T, Kasper W, Kahl C, Jahnchen E (1978) Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol 5:187-188
18. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J (2006) The c.-1639G[Apolymorphismof theVKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133:183-187
19. Morin S, Bodin L, Loriot MA, Thijssen HH, Robert A, Strabach S, Verstuyft C, Tregouet DA, Dubert L, Laurent-Puig P, Funck-Brentano C, Jaillon P, Beaune PH, Becquemont L (2004) Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 75:403-414
20. Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH (2006) A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol 62:617-620
21. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293
22. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
23. Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80:13-22
24. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106:2329-2333
25. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450
26. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F (2008) Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 9:1237-1250
27. Sychev DA, Ignat'ev IV, Kropacheva ES, Emel'ianov NV, Milovanova VV, Naumova Iu A, Kosovskaia AV, Dobrovol'skii OB, Tashenova AI, Panchenko EP, Kukes VG (2011) CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications. Vestn Ross Akad Med Nauk 3:7-10
28. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-And inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16:101-110
29. Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA, Straus S, Stricker BH, Visser LE (2011) Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 153:379-385
30. Thijssen HH, Ritzen B (2003) Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 74:61-68
31. Thijssen HH, Flinois JP, Beaune PH (2000) Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 28:1284-1290
32. Thijssen HH, Drittij MJ, Vervoort LM, de Vries-Hanje JC (2001) Altered pharmacokinetics of R-And S-Acenocoumarol in a subject heterozygous for CYP2C93. Clin Pharmacol Ther 70:292-298
33. Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists: Warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44:1227-1246
34. Van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, Levi M, Sturk A (2009) Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: Prospective validation of a prescription model. J Thromb Thrombolysis 27:207-214
35. van Leeuwen Y, Rosendaal FR, van der Meer FJ (2008) The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon. Thromb Res 123:225-230
36. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH (2011) Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J (Epub ahead of print)
37. Xie HG, Prasad HC, Kim RB, Stein CM (2002) CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257-1270
38. Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh HK, Wennerholm A (2002) Analysis of CYP2C9-5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 58:555-558
39. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751